目的：对比临床试验期间国内外临床试验方案、研究者手册、知情同意书这三个关键要素中关于药物警戒监管的差异，为我国科学监管提出建议，从而加强新药临床试验期间安全性风险控制及受试者保护。方法：通过文献和法规研究，对比临床试验期间国内外临床试验方案、研究者手册、知情同意书这三个关键要素中关于药物警戒监管的差异，就如何更好应用临床试验方案、研究者手册、知情同意书保护受试者展开讨论。结果与结论：临床试验方案、研究者手册、知情同意书是临床研究中关于风险控制和受试者保护的关键安全性管理要素。我国临床试验期间上述三项管理要求的指导原则尚待完善，目前规定大多仅基于ICH的普遍要求，缺少基于国内行业现状的监管及指导。
Objective: To put forward suggestions for China's scientifi c supervision in order to strengthen the risk control on safety and protection on subjects during clinical trials of new drugs after comparing the diff erences of pharmacovigilance supervision at home and abroad about the three key elements of clinical trial protocols, investigator's brochure, and informed consent forms during clinical trials. Methods: Through literature search and reviews of regulations, the diff erences in domestic and foreign regulations on pharmacovigilance about thehree key elements of clinical trial protocols, investigator's brochure and informed consent forms were compared. Discussions were conducted on how to better apply clinical trial protocols, investigator's brochure and informed consent forms to protect subjects. Results and Conclusion: The clinical trial protocols, investigator's brochure, and informed consent forms are the key safety management elements for risk control and protection on subjects in clinical trials. The guidelines for the above three management requirements during clinical trials in China need to be further improved. Most of the current regulations are formed only to meet the general requirements of ICH and there is a lack of supervisions and guidances consistent with the current situation of the domestic industries.
[1] International Council for Harmonisation(ICH).ICH Harmonised Guideline:Integrated Addendum to ICH E6(R1):Guideline for Good Clinical Practice E6(R2)[EB/OL].(2016)[2021-03-25].https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.
[2] International Council for Harmonisation(ICH).ICH Harmonised Guideline:Optimisation of Safety Data Collection E19[EB/OL].(2019)[2021-03-25].https://database.ich.org/sites/default/files/E19_EWG_Draft_ Guideline.pdf.
[3] National Institutes of Health(NIH).Protocol Templates for Clinical Trials[EB/OL].(2021)[2021-03-25].https://grants.nih.gov/policy/clinical-trials/protocoltemplate.
[4] European Commission.Regulation(EU)No 536/2014 of the European Parliament and of the Council-on Clinical Trials on Medicinal Products for Human Use,and Repealing Directive 2001/20/EC[EB/OL].(2014)[2021-03-25].https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2014_536/reg_2014_536_en.pdf.
[5] European Commission.EudraLex-Volume 10-Clinical Trials Guidelines[EB/OL].[2021-03-25].https://ec.europa.eu/health/medicinal-products/eudralex/eudralexvolume-10_en#set-of-documents-applicable-to-clinicaltrials-that-will-be-authorised-under-regulation-eu-no5362014-once-it-becomes-applicable.
[6] The Heads of Medicines Agencies.Recommendations Related to Contraception and Pregnancy Testing in Clinical Trials[EB/OL].(2014)[2021-03-25].https://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_ HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_ Contraception.pdf.
[7] The Heads of Medicines Agencies.Q&A Document– Reference Safety Information[EB/OL].(2017)[2021-03-25].https://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2017_11_CTFG_Question_and_Answer_on_Reference_Safety_Information_2017.pdf.
[8] The Heads of Medicines Agencies.Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the Approximation of the Laws,Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use[EB/OL].[2021-03-25].https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A0200 1L0020-20090807.
[9] FDA.21 CFR§50.25(c)Questions and Answers on Informed Consent Elements[EB/OL].(2012)[2021-03-25].https://www.fda.gov/regulatory-information/searchfda-guidance-documents/questions-and-answersinformed-consent-elements-21-cfr-ss-5025c.
[10] The Council for International Organizations of Medical Sciences(CIOMS),World Health Organization WHO[EB/OL].[2021-03-25].International Ethical Guidelines for Health-related Research Involving Humans.https://cioms.ch/.
[11] 国家药品监督管理局,国家卫生健康委员会.药物临床试验质量管理规范[EB/OL].(2020)[2021-03-25].https://www.nmpa.gov.cn/zhuanti/ypzhcglbf/ypzhcglbfzhc wj/20200426162401243.htm.
